Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
oral hexavalent reassortant rotavirus attenuated live vaccine (Vero cell)
- Development stage
- Unknown
- Lead developer
- Wuhan Institute of Biological Products
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
The oral hexavalent reassortant rotavirus attenuated live vaccine (Vero cell) is a multivalent, live-attenuated viral vaccine developed for the prevention of rotavirus gastroenteritis in infants. Produced using Vero cell culture technology, the vaccine contains six reassortant rotavirus strains, typically covering the G1, G2, G3, G4, G9, and P[8] serotypes. These genotypes represent the most common causes of severe diarrhea and dehydration in children globally. The vaccine is administered orally and works by mimicking a natural infection to stimulate the immune system to produce neutralizing antibodies and local intestinal immunity (IgA) against Rotavirus A. It is currently undergoing Phase 3 clinical trials in China, including studies to evaluate batch-to-batch consistency, immunogenicity, and safety in infants aged 6 to 12 weeks.
- Other names
- hexavalent rotavirus vaccineHRV6HRV-6HRV 6oral hexavalent reassortant rotavirus live vaccine
02
Targets
VP7 (Outer capsid glycoprotein VP7)
Beyond the preview
Go deeper on oral hexavalent reassortant rotavirus attenuated live vaccine (Vero cell).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on oral hexavalent reassortant rotavirus attenuated live vaccine (Vero cell).